New York, New York–(Newsfile Corp. – December 25, 2024) – Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC (LON:) (” AstraZeneca (NASDAQ:)” or the “Company”) (NASDAQ: AZN) and certain of its officers.
Definition of category
This lawsuit seeks to recover damages against the Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period “). ). These investors are encouraged to join this case by visiting the company's website: bgandg.com/AZN.
Case details
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) AstraZeneca was involved in insurance fraud in China; (2) as a result, AstraZeneca faced increased legal exposure in China, which ultimately resulted in the President of AstraZeneca China being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca reduced its legal risks; (4) the foregoing, once disclosed, could materially harm AstraZeneca's business activities in China; and (5) as a result, Defendants' statements about their business, operations, and future prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims, investors suffered damages.
What's next?
A class action lawsuit has already been filed. If you would like to review a copy of the complaint, you can visit the company's website: bgandg.com/AZN. Or you can contact Peritz Bronstein, Esq. Or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffer a loss in AstraZeneca, you have until February 21, 2025 to ask the court to appoint you as lead plaintiff. Your ability to participate in any recovery does not require that you serve as lead plaintiff.
There is no cost to you
We represent investors in class actions on a contingency fee basis. This means that we will ask the court to reimburse us for out-of-pocket expenses and attorney fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Goertz and Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud and shareholder derivative litigation. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook (NASDAQ:) or Instagram.
Lawyer advertisement. Previous results do not guarantee similar results.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234995
